The applications of prostate mpMRI in clinical decisions, related to the need for prostate biopsy and which areas to biopsy, have rapidly increased over the past few years. After the biopsy, clinicians also have series of methods to determine the aggressiveness of the prostate cancer. The National Comprehensive Cancer Network [NCCN]1 risk groups is one of the most commonly used system. The primary intent of the NCCN is to predict biochemical recurrance rather than survival outcomes such as distant metastasis (DM). Recently, NCCN was integrated with a genomic classifier, Decipher,2 optimized to predict the risk of DM. The resultant new 3-tier risk clinical-genomic classification (CGC) system grouped the patients in low-, intermidiate- and high-risk.3 Here we present radiomics-based approach to predict the low risk group based on the novel CGC.
This abstract and the presentation materials are available to members only; a login is required.